Kolexia
Guigay Joel Pneumologie
Guigay Joel
Pneumologie
Centre Antoine Lacassagne
Nice, France
220 Activités
10 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Carcinomes Carcinome épidermoïde Tumeurs de la tête et du cou Carcinome épidermoïde de la tête et du cou Récidive tumorale locale Métastase tumorale Tumeurs du poumon Cancer du nasopharynx Tumeurs épidermoïdes

Collaborateurs

Voir plus
Fayette Jérôme
Fayette Jérôme
Centre Léon-Bérard, Lyon, France
Even Caroline
Even Caroline
Gustave-Roussy, Villejuif, France
Saada-Bouzid Esma
Saada-Bouzid Esma
Centre Antoine Lacassagne, Nice, France
Auperin Anne
Auperin Anne
Gustave-Roussy, Villejuif, France

Industries

Voir plus
B3TSI
45 collaboration(s)
Dernière en 2023
Merck
23 collaboration(s)
Dernière en 2023
Merck-Serono
12 collaboration(s)
Dernière en 2022
MSD
11 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
Cetuximab versus methotrexate in first-line treatment of older, frail patients with inoperable recurrent or metastatic head and neck cancer (ELAN UNFIT): a randomised, open-label, phase 3 trial.
The Lancet. Healthy longevity   05 mars 2024
ELAN-UNFIT: Multicentric Randomized Phase III Trial Comparing Methotrexate and Cetuximab in First-line Treatment of Recurrent and/or Metastatic Squamous Cell Head and Neck Cancer in Elderly Unfit Patients According to Geriatric Evaluation
Essai Clinique (Merck-Serono)   07 février 2024
MegaMOST - A Multicenter, Open-label, Biology Driven, Phase II Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations /Characteristics in Advanced / Metastatic Tumors.
Essai Clinique (Centre Léon-Bérard)   16 novembre 2023
UPSTREAM: A Pilot Study of Personalized Biomarker-based Treatment Strategy or Immunotherapy in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
Essai Clinique (Organisation européenne pour la recherche et le traitement du cancer)   02 novembre 2023
Cetuximab every 2 weeks versus standard weekly dosing administration schedule.
Future oncology (London, England)   18 octobre 2023
938P Nivolumab (nivo) in recurrent and/or metastatic squamous cell carcinoma of head and neck (R/M SCCHN): real-world effectiveness, quality of life (QoL) of patients and their caregivers in France (ProNiHN study)
Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023.   01 octobre 2023
REACH: A Phase III Randomized Trial of Avelumab-cetuximab-Radiotherapy Versus Standards of Care in Locally Advanced Squamous Cell Carcinoma of the Head and Neck
Essai Clinique (Groupe d'Oncologie Radiothérapie Tête Et Cou)   19 juin 2023
Chemotherapy postimmunotherapy for recurrent metastatic head and neck squamous cell carcinoma.
Current opinion in oncology   14 mars 2023
Pembrolizumab versus cetuximab concurrent with radiotherapy in patients with locally advanced squamous cell carcinoma of head and neck unfit for cisplatin (GORTEC 2015-01 PembroRad): a multicenter, randomized, phase II trial.
Annals of oncology : official journal of the European Society for Medical Oncology   28 octobre 2022
Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141): An Open Label, Randomized Phase 3 Clinical Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Platinum-refractory Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Essai Clinique (BMS)   06 septembre 2022